ASH 2022 Conference Coverage

 

MDS and MPN
18:24

ASH 2022 Conference Coverage

Ropeginterferon Alfa-2b vs. Standard Therapy for Low-Risk Pts With PV: Final Results of Low-PV Randomized Phase II Trial

FEATURING Tiziano Barbui
  • 181 views
  • May 8, 2023
05:09

ASH 2022 Conference Coverage

MEDALIST Study: Multiple Episodes of Transfusion Independence With Luspatercept Treatment and the Impact of Dose Escalation in Pts With LR-MDS

FEATURING Uwe Platzbecker
  • 191 views
  • February 16, 2023
31:13

ASH 2022 Conference Coverage

Selected Updates in MDS

FEATURING Amer Zeidan
  • 486 views
  • February 14, 2023
  • 2
08:24

ASH 2022 Conference Coverage

Phase 2 FIGHT-203 Study: Pemigatinib in Pts With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

FEATURING Alessandro Vannucchi
  • 436 views
  • February 14, 2023
  • 1
09:27

ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

FEATURING Mary Frances McMullin
  • 1,145 views
  • February 1, 2023
  • 6
03:41

ASH 2022 Conference Coverage

ASH 2022: Venetoclax Combined With Cladribine, Idarubicin, Cytarabine (CLIA) as Induction Therapy in Pts With Newly Diagnosed AML and High-Risk MDS

FEATURING Gautam Borthakur
  • 175 views
  • January 28, 2023
  • 1
06:04

ASH 2022 Conference Coverage

ASH 2022 Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for MDS

FEATURING Matteo Della Porta
  • 49 views
  • January 19, 2023
11:00

ASH 2022 Conference Coverage

ASH 2022: Management of Accelerated and Blast-Phase MPN

FEATURING Raajit Rampal
  • 57 views
  • January 11, 2023
  • 2
10:14

ASH 2022 Conference Coverage

ASH 2022: Navitoclax and Ruxolitinib in JAKi-Naïve Patients With MF Mediates Responses Suggestive of Disease Modification in the Phase 2 REFINE Study

FEATURING Francesco Passamonti
  • 77 views
  • January 4, 2023
27:09

ASH 2022 Conference Coverage

ASH 2022: What Is Complete HLA Match in 2022?

FEATURING Stephen Spellman
  • 191 views
  • January 4, 2023
  • 2
06:34

ASH 2022 Conference Coverage

ASH 2022 Outcomes of Patients With Accelerated/Blast-Phase MPNs in the Current Era of Myeloid Therapies

FEATURING Anand Patel
  • 107 views
  • January 3, 2023
09:54

ASH 2022 Conference Coverage

ASH 2022 Phase II Study of Myeloablative 8/8- or 7/8-Matched AlloSCT With Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil

FEATURING Alex Hoover
  • 28 views
  • December 28, 2022
06:06

ASH 2022 Conference Coverage

Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in LR-MDS

FEATURING Rami Komrokji
  • 280 views
  • December 22, 2022
  • 3
06:55

ASH 2022 Conference Coverage

Luspatercept for Treatment of LR-MDS: Real World Data Replicates MEDALIST Study Results and Confirms Activity Among HMAs and Lenalidomide Treated Pts

FEATURING Rami Komrokji
  • 334 views
  • December 22, 2022
  • 1
07:02

ASH 2022 Conference Coverage

ASH 2022 Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Pts With Hypomethylating Agent Failure MDS

FEATURING David Sallman
  • 40 views
  • December 22, 2022
10:30

ASH 2022 Conference Coverage

ASH 2022 Primary Results of STIMULUS-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition With Sabatolimab Added to HMAs in Adult Patients With Higher-Risk MDS

FEATURING Amer Zeidan
  • 131 views
  • December 21, 2022
06:10

ASH 2022 Conference Coverage

Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safety, & Tolerability of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients With Polycythemia Vera

FEATURING John Mascarenhas
  • 134 views
  • December 21, 2022
  • 2
08:11

ASH 2022 Conference Coverage

Validation of 2022 WHO & ICC Classifications in MDS - An Analysis on Behalf of the icMDS

FEATURING Somedeb Ball
  • 191 views
  • December 19, 2022
  • 4
08:02

ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil as the New Standard for GVHD Prophylaxis in Reduced Intensity Conditioning

FEATURING Shernan Holtan
  • 350 views
  • December 19, 2022
  • 1
11:40

ASH 2022 Conference Coverage

ASH 2022 Efficacy & Safety of Add-On Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Pts With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

FEATURING Abdulraheem Yacoub
  • 57 views
  • December 16, 2022
08:57

ASH 2022 Conference Coverage

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant AML and HR-MDS

FEATURING Jan Bewersdorf
  • 92 views
  • December 16, 2022
  • 1
11:20

ASH 2022 Conference Coverage

Updated Results From the Momentum Phase 3 Study of Momelotinib vs. Danazol in Symptomatic and Anemic MF Pts Previously Treated With a JAK Inhibitor

FEATURING Aaron Gerds
  • 231 views
  • December 16, 2022